|
Q4 FY2025
As of Dec 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Current assets | |||||
| Cash and cash equivalents | |||||
| Deposits and restricted cash | |||||
| Trade receivables, net | |||||
| Other receivables | |||||
| Inventory | |||||
| Biological assets | |||||
| Financial assets measured at fair value through profit or loss | |||||
| Total Current assets | |||||
| Non-current assets | |||||
| Other receivables | |||||
| Property, plant and equipment and right-of-use assets | |||||
| Goodwill | |||||
| Loan measured at fair value through profit or loss | |||||
| Deferred tax assets | |||||
| Financial assets measured at fair value through profit or loss | |||||
| Investment in associate and loans | |||||
| Total Non-current assets | |||||
| Total assets | |||||
| Current liabilities | |||||
| Short term loans and current maturities | |||||
| Trade payables | |||||
| Other payables | |||||
| Contingent consideration | |||||
| Short term loan from controlling shareholder | |||||
| Financial liability with respect to shares and warrants to be issued | |||||
| Total Current liabilities | |||||
| Non-current liabilities | |||||
| Long term loans | |||||
| Liabilities in respect of employee benefits | |||||
| Lease liability | |||||
| Total Non-current liabilities | |||||
| Total liabilities | |||||
| Equity | |||||
| Share capital, premium and other reserves | |||||
| Capital reserve for transactions with controlling shareholder | |||||
| Capital reserve for transactions with non-controlling interests | |||||
| Receipts on account of warrants | |||||
| Accumulated losses | |||||
| Equity attributable to owners of the Company | |||||
| Non-controlling interests | |||||
| Total equity | |||||
| Total equity and liabilities | |||||
Loading...
